paladin/BDAZ - If the question is; Does Zenith get 12% off the top in a buyout scenario then the answer is, absolutely not. Zenith is only entitled to a percentage of Net Apo Revenue(Sales revenue of apabetalone). There is a formula which starts at 8% and increases to 12% of that Net Apo Revenue, for every area outside of China and the territories that are under license to Hepalink. In those licensed territories it is a 6% royalty plus sales milestones. As far as I am awear Zenith is not entitled to any of the proceeds of the the sales of the company Resverlogix.